Vaxart (Vaxart) Change In Receivables : $-2.99 Mil (TTM As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Vaxart Change In Receivables?

Vaxart's change in receivables for the quarter that ended in Dec. 2023 was $-2.58 Mil. It means Vaxart's Accounts Receivable increased by $2.58 Mil from Sep. 2023 to Dec. 2023 .

Vaxart's change in receivables for the fiscal year that ended in Dec. 2023 was $-2.99 Mil. It means Vaxart's Accounts Receivable increased by $2.99 Mil from Dec. 2022 to Dec. 2023 .

Vaxart's Accounts Receivable for the quarter that ended in Dec. 2023 was $3.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vaxart's Days Sales Outstanding for the three months ended in Dec. 2023 was 41.43.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vaxart's liquidation value for the three months ended in Dec. 2023 was $7.94 Mil.

Vaxart Change In Receivables Historical Data

The historical data trend for Vaxart's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Change In Receivables Chart

Vaxart Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.82

3.29

0.26

0.05

-2.99

Vaxart Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-0.02	-0.24	0.24	-0.40	-2.58

Vaxart Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.99 Mil.

Vaxart (NAS:VXRT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vaxart's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3.008	/	6.625	*	91
=	41.43

2. In Ben Graham's calculation of liquidation value, Vaxart's accounts receivable are only considered to be worth 75% of book value:

Vaxart's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	39.713	-	34.025	+	0.75 * 3.008	+	0.5 * 0
=	7.94

Vaxart Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vaxart's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart (Vaxart) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

NB11:Germany NB11:Germany

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Executives

W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee	officer: Chief Financial Officer	C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron	director	6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg	officer: SVP, General Counsel	C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid	director	C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd	officer: VP, Corporate Controller, PAO	3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings	officer: Chief Medical Officer	1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington	director	9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker	officer: Chief Scientific Officer	385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour	director, officer: President and Chief Executive	385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037